Half-Year 2022 Financial and Clinical Trials Update
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
Metastatic and/or recurrent PD-L1+
cervical cancer (CC)
Neoadjuvant and adjuvant NSCLC
Phase/study
# of patients
Phase II
SKYSCRAPER-04
N=172
ARM A: Tiragolumab plus Tecentriq
ARM B: Tecentriq
Design
■ Objective response rate
Primary endpoint
FPI Q2 2020
Status
CT Identifier
NCT04300647
NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1
Phase II
SKYSCRAPER-05
N=82
1L non-squamous NSCLC
Phase II/III
SKYSCRAPER-06
N=500
"
■ ARM A: (PD-L1 high) neoadjuvant tiragolumab
plus Tecentriq followed by adjuvant
tiragolumab plus Tecentriq or adjuvant
chemotherapy
■ ARM B: (PD-L1 all-comers) neoadjuvant
tiragolumab plus Tecentriq plus chemo
followed by adjuvant tiragolumab plus
Tecentriq
■ Pathologic complete response, major
pathological response and safety
"
FPI Q2 2021
"
ARM A: Tiragolumab plus Tecentriq plus
pemetrexed plus chemo followed by
maintenance tiragolumab plus Tecentriq plus
pemetrexed
ARM B: Placebo plus pembrolizumab plus
pemetrexed plus chemo followed by
maintenance placebo plus pembrolizumab
plus pemetrexed
■ Objective response rate, progression-free
survival and overall survival
☐
FPI Q4 2020
NCT04832854
NCT04619797
Roche
128
OncologyView entire presentation